Torezolid phosphate is primarily used as an antibiotic in the treatment of serious bacterial infections, particularly those caused by Gram-positive bacteria. It is effective against drug-resistant strains, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). This makes it a valuable option in hospitals for managing complicated skin and soft tissue infections where other antibiotics may fail. It is administered intravenously or orally, offering flexibility in treatment regimens. Its mechanism of action involves inhibiting bacterial protein synthesis, which helps in stopping the growth and spread of the infection. Due to its potency and targeted action, it is often reserved for cases where first-line treatments are ineffective.